

Jacob A Sloane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7194709/publications.pdf>

Version: 2024-02-01

47
papers

2,277
citations

331642

21
h-index

223791

46
g-index

50
all docs

50
docs citations

50
times ranked

3677
citing authors

#	ARTICLE	IF	CITATIONS
1	Toll-like receptor 8 functions as a negative regulator of neurite outgrowth and inducer of neuronal apoptosis. <i>Journal of Cell Biology</i> , 2006, 175, 209-215.	5.2	247
2	Increased microglial activation and protein nitration in white matter of the aging monkey†. <i>Neurobiology of Aging</i> , 1999, 20, 395-405.	3.1	191
3	Toll-Like Receptor 3 Is a Potent Negative Regulator of Axonal Growth in Mammals. <i>Journal of Neuroscience</i> , 2007, 27, 13033-13041.	3.6	191
4	In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis. <i>Brain</i> , 2017, 140, 2912-2926.	7.6	159
5	Neuroinflammatory component of gray matter pathology in multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 776-790.	5.3	150
6	The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS. <i>Journal of Neuroscience</i> , 2013, 33, 1927-1939.	3.6	142
7	A gradient in cortical pathology in multiple sclerosis by in vivo quantitative 7 T imaging. <i>Brain</i> , 2015, 138, 932-945.	7.6	121
8	WAVE1 Is Required for Oligodendrocyte Morphogenesis and Normal CNS Myelination. <i>Journal of Neuroscience</i> , 2006, 26, 5849-5859.	3.6	89
9	Metalloendopeptidase EC 3.4.24.15 Is Necessary for Alzheimer's Amyloid- β^2 Peptide Degradation. <i>Journal of Biological Chemistry</i> , 1999, 274, 18777-18784.	3.4	88
10	A Clear and Present Danger: Endogenous Ligands of Toll-like Receptors. <i>NeuroMolecular Medicine</i> , 2010, 12, 149-163.	3.4	81
11	Astrocytic hypertrophy and altered GFAP degradation with age in subcortical white matter of the rhesus monkey. <i>Brain Research</i> , 2000, 862, 1-10.	2.2	78
12	Regulation of remyelination in multiple sclerosis. <i>FEBS Letters</i> , 2011, 585, 3821-3828.	2.8	77
13	Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. <i>Neuroscience Letters</i> , 1997, 225, 73-76.	2.1	67
14	Longitudinal Characterization of Cortical Lesion Development and Evolution in Multiple Sclerosis with 7.0-T MRI. <i>Radiology</i> , 2019, 291, 740-749.	7.3	56
15	COVID-19 in teriflunomide-treated patients with multiple sclerosis. <i>Journal of Neurology</i> , 2020, 267, 2790-2796.	3.6	56
16	JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. <i>Annals of Neurology</i> , 2014, 75, 925-934.	5.3	44
17	Myosin Va Controls Oligodendrocyte Morphogenesis and Myelination. <i>Journal of Neuroscience</i> , 2007, 27, 11366-11375.	3.6	37
18	Beyond focal cortical lesions in MS. <i>Neurology</i> , 2015, 85, 1702-1709.	1.1	36

#	ARTICLE	IF	CITATIONS
19	Heterogeneous pathological processes account for thalamic degeneration in multiple sclerosis: Insights from 7T imaging. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1433-1444.	3.0	32
20	Risk factors for lymphopenia in patients with relapsing/remitting multiple sclerosis treated with dimethyl fumarate. <i>Journal of Neurology</i> , 2020, 267, 125-131.	3.6	28
21	The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T2* mapping at 7 T MRI. <i>NeuroImage: Clinical</i> , 2016, 12, 879-886.	2.7	27
22	Cortical and phase rim lesions on 7 T MRI as markers of multiple sclerosis disease progression. <i>Brain Communications</i> , 2021, 3, fcab134.	3.3	24
23	Profiles of cortical inflammation in multiple sclerosis by 11C-PBR28 MR-PET and 7 Tesla imaging. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1497-1509.	3.0	22
24	7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis. <i>Brain</i> , 2020, 143, 2973-2987.	7.6	22
25	Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes. <i>Neurology and Therapy</i> , 2019, 8, 109-119.	3.2	20
26	WAVE1 and Regulation of Actin Nucleation in Myelination. <i>Neuroscientist</i> , 2007, 13, 486-491.	3.5	19
27	Social-emotional aspects of quality of life in multiple sclerosis. <i>Psychology, Health and Medicine</i> , 2018, 23, 411-423.	2.4	17
28	Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients. <i>Journal of Neurology</i> , 2018, 265, 2342-2345.	3.6	17
29	Changes in structural network are associated with cortical demyelination in early multiple sclerosis. <i>Human Brain Mapping</i> , 2018, 39, 2133-2146.	3.6	16
30	Characterization of thalamic lesions and their correlates in multiple sclerosis by ultra-high-field MRI. <i>Multiple Sclerosis Journal</i> , 2021, 27, 674-683.	3.0	15
31	Biotin supplementation in MS clinically valuable but can alter multiple blood test results. <i>Multiple Sclerosis Journal</i> , 2017, 23, 619-620.	3.0	14
32	Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors. <i>Journal of Neurology</i> , 2016, 263, 1511-1517.	3.6	13
33	Is the Relationship between Cortical and White Matter Pathologic Changes in Multiple Sclerosis Spatially Specific? A Multimodal 7-T and 3-T MR Imaging Study with Surface and Tract-based Analysis. <i>Radiology</i> , 2016, 278, 524-535.	7.3	11
34	Leptomeningeal Enhancement on 3D-FLAIR MRI in Multiple Sclerosis: Systematic Observations in Clinical Practice. <i>Journal of Neuroimaging</i> , 2020, 30, 917-929.	2.0	11
35	The relevance of multiple sclerosis cortical lesions on cortical thinning and their clinical impact as assessed by 7.0-T MRI. <i>Journal of Neurology</i> , 2021, 268, 2473-2481.	3.6	11
36	Unilateral Relapsing Primary Angiitis of the CNS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	9

#	ARTICLE	IF	CITATIONS
37	Prevalence of Latent Tuberculosis in the Multiple Sclerosis Clinic and Effect of Multiple Sclerosis Treatment on Tuberculosis Testing. <i>International Journal of MS Care</i> , 2021, 23, 26-30.	1.0	9
38	A New England COVID-19 Registry of Patients With CNS Demyelinating Disease. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, e1046.	6.0	6
39	No Evidence of Disease Activity in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 835.	9.0	5
40	Brainstem lesions are associated with sleep apnea in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732096795.	1.0	4
41	CLICK-MS and MASTER-2 Phase IVÂtrial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. <i>Neurodegenerative Disease Management</i> , 2021, 11, 99-111.	2.2	4
42	Quantitative 7-Tesla Imaging of Cortical Myelin Changes in Early Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021, 12, 714820.	2.4	4
43	Challenges in the diagnosis and treatment of CNS demyelinating disorders in Zambia. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731665711.	1.0	2
44	PML-IRIS in an HIV-2-infected patient presenting as Bellâ€™s palsy. <i>Journal of NeuroVirology</i> , 2017, 23, 789-792.	2.1	2
45	Extended B-cell depletion beyond 6-months in patients receiving ocrelizumab or rituximab for CNS demyelinating disease. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103505.	2.0	2
46	Blunted Post-COVID-19 Humoral Immunity in Patients With CNS Demyelinating Disorders on Anti-CD20 Treatments. <i>Frontiers in Neurology</i> , 2022, 13, 843081.	2.4	1
47	045â€¦Delayed-release dimethyl fumarate demonstrated no difference in clinical outcomes versus fingolimod in patients with relapsing-remitting multiple sclerosis: results from the real-world effect study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A19.1-A19.	1.9	0